Kenneth J. Luppi

Part of Flynn Management LLC, Deerfield Management LP is a company that provides investment advice. The company is based in New York, NY. Michael A. Foley has been the CEO of the company since 2018.

Genesis Capital Advisors LLC provides investment advice and real estate investment products to pension funds, endowments, and private investors. The company was founded by Ethan Benovitz in 2008 and is headquartered in New Rochelle, NY.

Conventus Orthopaedics, Inc. operates as a medical device company for fracture treatment. It focuses on creating less invasive solutions for fractures in and around the joints. The firm offers distal radial and wrist fracture repair products. Its products include distal radius and proximal humerus. The company was founded by Michael P. Brenzel and Paul J. Hindrichs in 2009 and is headquartered in Maple Grove, MN.

Claret Medical, Inc. develops a cerebral protection technology designed to protect patients from the risk of stroke during left heart procedures and vascular interventions. It focuses on addressing the problem of stroke during transcatheter aortic valve replacement (TAVR), a significant unmet clinical need. The company was founded by Farhad Khosravi and Randy Lashinski in 2009 and is headquartered in Santa Rosa, CA.

Iterion Therapeutics, Inc. provides pharmaceuticals services. The firm products are used in the treatment of colorectal, hematopoietic, and other targeted cancers. The company was founded by Jonathan P. Northrup in 2010 and is headquartered in Houston, TX.

KellBenx, Inc. develops non-invasive prenatal diagnostics for analyzing genetic disorders and to determine a woman's risk of preterm delivery. The company was founded in 2010 and is headquartered in Great River, NY.

Element Science, Inc. operates as a medical device and digital health company. It develops a wearable platform solution with proprietary technology in wearable patches, electrical design, machine learning algorithms and digital solutions. The company was founded by Uday N. Kumar in 2011 and is headquartered in San Francisco, CA.

Farapulse, Inc. engages in the development of medical devices. Its products are: Endo Farawave, a percutaneous catheter designed to create transmural and contiguous lesions on the endocardium of the left atrium to isolate the pulmonary veins and EPI Faraone, s designed to create a box lesion around all pulmonary veins from an epicardial placement of the catheter for the treatment of atrial fibrillation. The company was founded by Steven Mickelsen in 2014 and is headquartered in Iowa City, IA.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Longitude Capital Management Co LLC (Longitude Capital) is a venture capital firm founded in 2006 by Juliet Trammenoms Bakker, Patrick Enright, David Hirsch and Marc-Henri Galletti. The firm is headquartered in Menlo Park, California.

NeoChord, Inc. develops medical devices. It offers NeoChord, a disposable device that replaces damaged chordae through a small incision while the heart is beating. The company was founded in 2007 and is headquartered in St. Louis Park, MN.

TVA Medical, Inc. engages in the development of invasive therapies for end-stage renal disease and peripheral vascular disease. It provides catheter-based system that allows physicians to create an arterio-venous fistula to deliver hemodialysis to patients suffering from kidney failure. The company was founded by William E. Cohn and Adam L. Berm In 2008 and is headquartered in Austin, TX.

InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA.

Epic Sciences, Inc. develops novel diagnostics to the treatment and management of cancer. It develops sensitive diagnostic tests to molecularly characterize circulating tumor cells in the blood. The firm also offers fluid-phase biopsy that identifies rare cell of interest in the blood; and provides cancer management through earlier diagnosis, staging and therapeutic selections. The company was founded by David M. Nelson in 2008 and is headquartered in San Diego, CA.

Zadara Storage, Inc. provides enterprise-class primary and secondary storage for the cloud that enables organizations to migrate existing mission-critical applications. It offers co-location, private, public and hybrid cloud solutions for business continuity, disaster recovery, performance acceleration, scalability, performance management, storage-as-a-service, data protection, infrastructure-as-a-service and unified storage. The company was founded by Nelson Nahum, Yair Hershko, Robi Hartman and Eli Shapira in 2011 and is headquartered in Irvine, CA.

V-Wave Ltd. engages in the development of implantable medical device for treating chronic heart failure. It offers V-Wave Shunt, which is a biocompatible inter-atrial unidirectional implant. The company was founded by Gad Keren and Yaacov Nitzan in 2009 and is headquartered in Caesarea, Israel.

Axon Therapies, Inc. develops treatment for heart failure. The company is headquartered in New York, NY.

MaxQ AI Ltd. is a clinical stage artificial intelligence company, which engages in the development of diagnostic solutions for the emergency room and acute care space. Its platform is designed to interpret and analyze medical images concurrently, and in conjunction with other patient data, such as age, comorbidities, medical history, genomic information, and laboratory test results to provide decision making support for the attending physician. The company was founded by Michael Rosenberg, Robert Jonathan Mehler and Jacob Cohen on October 2, 2013 and is headquartered in Tel Aviv, Israel.

CathWorks Ltd. develops medical devices for the interventional cardiology market. Its technology is based on processing visual information and automatic multi-layered algorithms. The company was founded by Guy Lavi and Ifat Lavi in 2013 and is headquartered in Raanana, Israel.

MTrap, Inc. engages in the development of novel therapeutic devices that interfere with the intense dialogue and crosstalk between the primary tumor and the microenvironment and represent a new disruptive approach to cancer treatment. The company was founded by Maybelle L. Jordan and is headquartered in Huntington, NY.

Millipede, Inc. engages in development of percutaneous solutions for mitral valve repair. It offers IRIS, a semi-rigid annuloplasty ring designed to replicate the gold standard in valve repair and clinical data. The company was founded by Steven F. Bolling, Todd D. Campbell and Jeremy A. Abbs in August 2012 and is headquartered in Santa Rosa, CA.

Renalguard Solutions, Inc. develops and manufactures medical devices for cardiac and vascular markets. Its product includes RenalGuard, which remove contrast dyes that are known to be toxic to the kidneys. The company is headquartered in Milford. MA.

Medical Microinstruments SpA develops and manufactures surgical micro-instruments. The firm focuses on clinical outcomes for patients undergoing microsurgery, and offers advanced microsurgical procedures, while reducing costs for patients, hospitals and for society at large. The company was founded by Giuseppe Prisco, Hannah Teichmann and Massimiliano Simi in 2015 and is headquartered in Calci, Italy.

Mount Sinai Genomics, Inc. operates online predictive health analysis platform for diagnosis, treatment and prevention of diseases. It offers Centrellis which analyzes and interprets extensive information about known inherited diseases, including related mutations, frequency across populations, and the penetrance and expressivity of genetic changes. The company was founded by Eric Schadt and is headquartered in Stamford, CT.

Encodia, Inc. engages in the research and development of protein analysis tools. The company was founded by Mark S. Chee, Michael Weiner, and Kevin Gunderson and is headquartered in San Diego, CA.

Adela, Inc. is a company that is developing technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). The company is based in Branford, CT. The company's genome-wide methylome enrichment platform captures extensive, biologically-relevant genomic information to maximize test performance and improve treatment decisions. Adela's approach to MRD testing is tissue agnostic, eliminating the burden of acquiring a tumor sample. The CEO of the company is Scott Bratman.

Pleno, Inc. is a company that specializes in multi-omic instrument platform technology for clinical testing and biomedical research. The company is based in San Diego, CA and was founded by Pieter van Rooyen, who has been the CEO since incorporation. The company's proprietary hypercoding™ technology uses signal processing techniques to provide targeted biological information with exceptional scale, precision, and performance.

Gold Candle Ltd. engages in the exploration and development of mineral assets. Its property includes a gold deposit located on the formerly producing, high-grade underground Kerr-Addison gold mine located in Virginiatown, Ontario. The company was founded by Michael Berns on December 23, 2014 and is headquartered in Toronto, Canada.

RapidPulse, Inc. is a medical device company that specializes in developing minimally invasive vascular products for ischemic stroke. The company is based in Miami, FL. The company is focused on advancing the development of the RapidPulse™ cyclic aspiration system, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC, a medical device incubator dedicated to developing innovative products in the medical device industry. The CEO of the company is Sean McBrayer.

Aurion Biotech, Inc. is a clinical-stage biotech company with offices in multiple locations. Aurion Biotech has initiated clinical trials in the US in 2023. The company is based in Seattle, WA. The company's mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech has received the prestigious Prix Galien award for best start-up in biotech. The company's first candidate is an off-the-shelf, clinically validated cell therapy for corneal care, which has received regulatory approval. The company is privately held and backed by leading investors, including Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision/KKR, and Visionary Ventures. Greg Kunst has been the CEO of the company since 2021.